ARGENX SE
ARGENX SE (ARGX): 13 pipeline candidates · 20 upcoming catalysts · ~5 mo cash runway · 44 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
5.0 months
D/E 0.19 · 0% dilution
Lead: Phase 3
13 candidates
20 upcoming, next in ~12d
N/A
A transparent, data-derived signal for ARGENX SEacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$55.8B
Cash
$3.5B
Quarterly Burn
$2.7B
Runway
5.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| argx-117 | Phase 2 |
| argx-119 | Phase 2 |
| argx-119 iv | Phase 2 |
| argx-124 | Phase 2 |
| argx-213 | Phase 2 |
| Efgartigimod | Phase 4 |
| Efgartigimod IV | Phase 4 |
| efgartigimod iv or efgartigimod ph20 sc | Phase 4 |
| Efgartigimod PH20 SC | Phase 4 |
| Empasiprubart | Phase 3 |
Showing 10 of 13 candidates. Sign up for full pipeline.
Upcoming Catalysts (20)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
472
Total value held
$16.57B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 5,083,464 | $3.70B |
| fmr llc | 4,991,034 | $3.64B |
| wellington management group llp | 1,021,457 | $745.9M |
| blackrock, inc. | 808,337 | $590.3M |
| rtw investments, lp | 709,446 | $518.1M |
| morgan stanley | 560,711 | $409.5M |
| alliancebernstein l.p. | 422,304 | $355.1M |
| bank of america corp /de/ | 400,117 | $292.2M |
| sands capital management, llc | 340,285 | $248.5M |
| bellevue group ag | 313,000 | $228.6M |
Showing top 10 of 472 institutional holders of ARGENX SE. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ARGENX SE's pipeline?
ARGENX SE (ARGX) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARGENX SE's lead drug candidate?
ARGENX SE's most advanced tracked candidate is argx-117 (Phase 2) for Delayed Graft Function; Multifocal Motor Neuropathy (MMN).
What is ARGENX SE's next catalyst?
ARGENX SE's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morpholog" — expected June 30, 2026.
What is ARGENX SE's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARGENX SE has approximately 5.0 months of cash runway.
What is ARGENX SE's market capitalization?
ARGENX SE's market capitalization is approximately $55.8B.
Get the full picture on ARGENX SE
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.